Jan 13, 2022BoardMeeting
BoardState of Illinois Drugs and Therapeutics Advisory Board Meeting Minutes
The board reviewed public testimony regarding several drug products and addressed new drug appeals, specifically approving Qelbree as a preferred option with prior authorization. The committee conducted clinical reviews for antiasthmatic drug classes, resulting in the addition of Anoro Ellipta, Incruse Ellipta, and Spiriva forms to the preferred list. Furthermore, the board reviewed and approved Lybalvi, Invega Hafyera, Myfembree, and Qulipta as preferred options with prior authorization requirements. The meeting also included a brief discussion on COVID-19 related vaccine and medication coverage.